We are delighted to welcome the newest addition to ANDHealth, Karen Clarke, as Director, Stakeholder Engagement and Operations.

Karen Clarke comes to ANDHealth from the Victorian Government where she was responsible for investments in medical technologies and pharmaceuticals companies, and worked to grow the sector through policy and strategy.

Previously, she was at the helm of the Victorian Platform Technologies Network, delivering a community of open-access facilities within universities and research institutes across the state, for use by researchers and industry alike. With a BA and BSc (Hons) from Monash University, Karen has experience in stem cell research and research infrastructure management. She is delighted to join the ANDHealth team and looks forward to building the digital health sector in Australia.

Funding for Australia’s first living database of health innovations across digital health, medtech and pharmaceuticals has today been announced. The project will catalogue and track the progress of health innovations under development in Australia and make the information accessible to all on a public online platform. The project will receive $100,000 from MTP Connect.

The project consortium is led by Canberra-based start-up Health Horizon, and includes ANDHealth as a consortium member.

Link to the living showcase: Australia's Health Innovation Showcase
For the media release, click here.
For the MTP Connect and Health Horizon Announcement, click here.

ANDHealth congratulates the ANDHealth+ 2017 cohort, DoseMe, Human Gas Capsule, PenPal, Perx, Seer Medical and Skin View.

ANDHealth’s first cohort of companies will benefit from a hands-on advisory group drawn from ANDHealth’s industry members, which include Novartis Pharmaceuticals, RMIT University, Planet Innovation, Curve Tomorrow, The Murdoch Children’s Research Institute, GP2U, HPM Executive, AusBiotech and HealthXL, that will work alongside each company to define and support a project which makes a significant contribution to their market readiness. In addition to the time and resources of the advisors, companies also can access $60k of project funds, media and communications support, intellectual property advice and access to a global network of digital health experts.

For the Press release, click here.

Category: News

Applications are open to the ANDHealth+ 2017 Program. ANDHealth+ provides critical financial and strategic input into mid-stage digital health companies looking to raise growth capital or enter international healthcare markets. Successful applicants will receive up to $60,000 funding to access specialist third party services and activities, and up to $100,000 of in kind support from ANDHealth’s commercial members and broader network. No transfer of equity or intellectual property rights is required to be a participant in the ANDHealth program. Apply until August 11 via our website

To view the press release, click here.

Australia’s medtech and digital health community gathered for a day of digital health key information, international trends and industry insight from national and international sector leaders on 23rd May. There were excellent networking sessions between speakers discussing key topics for startup and growth digital health companies:


  • VC’s on the risks and returns of investing in digital health – and what they need to see to make those investments

  • Regulatory advisors reviewing international regulatory strategies for securing approvals of evidence based digital health products;

  • Successful founders debated the challenges of defining business models in digital health that work – who will pay?

  • Showcase of leading mid-stage digital health companies, highlighting evidence-backed technologies & innovation developed here in Australia moving towards international markets.


Thanks to Allens for hosting the event. More information on speakers and program can be found here

ANDHealth is delighted to be covered in international trade journal Medical Device Daily in their article Australia launches national digital health effort to commercialise disruptive technology, Quoting MD Bronwyn Le Grice “The most important thing in delivering a digital health technology that impacts the clinical outcome for a patient is that point in time where the technology needs to have an evidence basis and clinical validation in order to make it investable and viable as a medical product.” The article is appended below.

Medical Technologies and Pharmaceuticals Industry Growth Centre – MTPConnect – today announced it will provide $7.4 million of funding over two years for 14 national projects in the medtech, biotech and pharmaceutical (MTP) sector. One is ANDHealth, a consortium led by the Murdoch Children’s Research Institute. ANDHealth represents the first program of its kind focused on ‘moving the needle’ for digital health companies in Australia needing to consolidate either clinical and/ or commercial validation for their technologies/ businesses in order to successfully raise capital or enter into a significant commercial partnership.